Skip Navigation

European Heart Journal 2004 25(15):1364; doi:10.1016/j.ehj.2004.05.025
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Koh, T.W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koh, T.W
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE

T.W Koh

Cardiac Catheterisation Laboratory, Department of Cardiology, London Chest Hospital, Bonner Road, London E2 9JX, UK Tel.: +44-208-983-2457; Fax: +44-208-983-2278

E-mail address: tatkoh@hotmail.com

The first 10% of the full text of this article appears below.

We agree with the main thrust of the argument in the recent article by Eriksson1 that long-term clopidogrel treatment (8 and 12 months) confers a small, or at most modest, advantage when compared to the standard 1-month treatment in patients undergoing percutaneous coronary intervention.

Eriksson . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?